Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Long-Term Investments (2020 - 2023)

Historic Long-Term Investments for Oncology Institute (DFPH) over the last 4 years, with Q2 2023 value amounting to $58.9 million.

  • Oncology Institute's Long-Term Investments changed N/A to $58.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was $58.9 million, marking a year-over-year change of. This contributed to the annual value of $58.4 million for FY2022, which is N/A changed from last year.
  • Per Oncology Institute's latest filing, its Long-Term Investments stood at $58.9 million for Q2 2023.
  • Oncology Institute's 5-year Long-Term Investments high stood at $230.3 million for Q1 2021, and its period low was $58.2 million during Q3 2022.
  • Over the past 4 years, Oncology Institute's median Long-Term Investments value was $230.0 million (recorded in 2021), while the average stood at $167.8 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first rose by 11.19% in 2021, then tumbled by 7469.05% in 2022.
  • Quarter analysis of 4 years shows Oncology Institute's Long-Term Investments stood at $230.3 million in 2020, then dropped by 0.1% to $230.0 million in 2021, then plummeted by 74.63% to $58.4 million in 2022, then rose by 1.01% to $58.9 million in 2023.
  • Its last three reported values are $58.9 million in Q2 2023, $58.8 million for Q1 2023, and $58.4 million during Q4 2022.